Radiopharmaceuticals have become one of the most closely watched corners of the biotech world, and Clarity Pharmaceuticals (ASX:CU6) sits right in the middle of the excitement. On 5 August 2026, the company provided an update from its SECuRE trial, reporting additional complete responses at the 8 GBq dose of its copper-67 therapy, 67Cu-SAR-bisPSMA, in patients with prostate cancer.

Complete responses, where signs of the targeted cancer are no longer detectable by the trial’s measures, are the kind of result that tends to draw attention. It is important, however, to keep the context in mind. These are early-stage trial observations in a defined patient group, not proof of a broadly effective treatment. Encouraging signals still need to be confirmed in larger, controlled studies before any firm conclusions can be drawn, so the update is best read as promising rather than definitive.

Clarity’s approach centres on copper isotopes, using copper-64 for diagnostic imaging and copper-67 for therapy. This diagnostic-and-therapeutic pairing, often called a theranostic strategy, is one reason the company has attracted a following. The appeal of copper-based systems lies partly in their potential logistical advantages, though the field remains competitive and commercial validation is still some way off.

Prostate cancer is a large indication, which helps explain why incremental clinical progress can generate outsized interest. At the same time, the radiopharmaceutical space has drawn significant Investment and several well-resourced players, meaning Clarity operates in an increasingly crowded arena.

For now, the story is one of accumulating early evidence. Additional complete responses at a key dose level add to the narrative Clarity is trying to build, but the path from encouraging trial data to an approved, widely used therapy is long and uncertain. Investors watching the copper-67 program will be looking for whether these signals hold up as the data set grows.